Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

By J. Korn, M. Mayes, M. Cerinic, M. Rainisio, J. Pope, E. Hachulla, É. Rich, P. Carpentier, J. Molitor, J. Seibold and 13 more. Arthritis & Rheumatism, 2004

743 citations recorded by the source corpus.

Subfields: Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine, Surgery

View Paper: https://www.semanticscholar.org/paper/0ef5d03a1bd879b3db928ee04ed18544dcfa487e

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. O. Kowal-Bielecka
2. J. Fransen
3. J. Avouac
4. M. Becker
5. A. Kułak
6. D. Khanna
7. Y. Allanore
8. O. Distler

Citations in the corpus

• Update of EULAR recommendations for the treatment of systemic sclerosis (2015, methodology): “[45] The reduction in the number of patients with a new DU was not statistically significant in any of the RAPIDS trials or their meta-analysis.[44-45] Neither trial indicated that bosentan is superior to placebo in the healing of SScrelated active DUs, as evaluated by the time to complete or partia”